NCT00461695View on ClinicalTrials.gov

Influence of Persistent CMV-infection on Immune Senescence

PHASE4CompletedINTERVENTIONAL

Enrollment

183

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

December 31, 2010

Conditions

Immune Senescence

Interventions

BIOLOGICAL

Vaccination against TBEV (FSME Immun CC)

Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.

Trial Locations (1)

Unknown

University Hospital Zurich, Department of Infectious Diseases and Hospital Epidemiology, Zurich

All Listed Sponsors

collaborator

Division of Infectious Diseases and Hospital Epidemiology

UNKNOWN

lead

University of Zurich

OTHER

NCT00461695 - Influence of Persistent CMV-infection on Immune Senescence | Biotech Hunter | Biotech Hunter